NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Trevi Therapeutics logo
$13.29 -0.36 (-2.64%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$13.29 0.00 (0.00%)
As of 11/16/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Advanced

Key Stats

Today's Range
$13.15
▼
$13.67
50-Day Range
$11.88
▼
$16.82
52-Week Range
$9.82
▼
$20.22
Volume
1.64 million shs
Average Volume
1.70 million shs
Market Capitalization
$1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.08
Consensus Rating
Moderate Buy

Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis.

Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.

Trevi is headquartered in New Haven, Connecticut, and its operations are centered on developing its drug candidate. Jennifer Good has served as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Trevi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

TRVI MarketRank™: 
2.16771097187 of 5 stars

Trevi Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 630th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Trevi Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Trevi Therapeutics has a consensus price target of $27.08, representing about 103.8% upside from its current price of $13.29.

  • Amount of Analyst Coverage

    Trevi Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Trevi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.64) per share.

  • Price to Book Value per Share Ratio

    Trevi Therapeutics has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.98% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 10.13, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 5.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Trevi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Trevi Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Trevi Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Trevi Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for TRVI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,648.00 in company stock.

  • Percentage Held by Insiders

    15.39% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trevi Therapeutics' insider trading history.
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRVI Stock News Headlines

FY2026 Earnings Estimate for TRVI Issued By HC Wainwright
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Trevi Therapeutics Q3 Loss Widens
Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcript
See More Headlines

TRVI Stock Analysis - Frequently Asked Questions

Trevi Therapeutics' stock was trading at $12.52 at the beginning of the year. Since then, TRVI stock has increased by 6.2% and is now trading at $13.29.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings data on Monday, November, 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.00.
Read the conference call transcript
.

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Trevi Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (2.48%), State Street Corp (2.30%), Marshall Wace LLP (2.21%) and Soleus Capital Management L.P. (1.91%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon, Lisa Delfini and Michael Thomas Heffernan.
View institutional ownership trends
.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include NVIDIA (NVDA), Definium Therapeutics (DFTX), Intel (INTC), Micron Technology (MU), Palantir Technologies (PLTR), Solid Biosciences (SLDB) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/09/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TRVI
CIK
1563880
Fax
N/A
Employees
34
Year Founded
2011

Price Target and Rating

High Price Target
$40.00
Low Price Target
$16.00
Potential Upside/Downside
+103.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.76 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.81%
Return on Assets
-23.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
38.86
Quick Ratio
37.28

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
6.27

Miscellaneous

Outstanding Shares
142,560,000
Free Float
120,619,000
Market Cap
$1.89 billion
Optionable
Optionable
Beta
1.15

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:TRVI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners